About

ADVANCING COMBINATION INTRATUMORAL IMMUNOTHERAPY

Syncromune is uniquely focused on developing intratumoral immunotherapy to fight cancer in a new way

CORPORATE OVERVIEW

OUR

STORY

A novel approach to fighting metastatic cancers

Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of novel intratumoral immunotherapies for metastatic solid tumors.  We are at the forefront of developing combination immunotherapies,  which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. 

The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation of immune cells. A vaccine is created from the patient’s own tumor, making it a personalized treatment for each patient. The platform is designed to enable the immune system to recognize and attack cancer throughout the body. Several clinical development programs are underway to advance Syncrovax™ into clinical trials. 

2020

FOUNDED

Fort Lauderdale, FL

HEADQUARTERS

Combination Intratumoral Immunotherapy

SPECIALTY

58 Patents Pending & Granted*

INTELLECTUAL PROPERTY

*As of 6/14/2022

OUR MISSION

is to be the world leader in optimized intratumoral immuno-oncology multi-component drug development and therapies. 

SYNCROMUNE TEAM

OUR

LEADERSHIP

Unsurpassed Dedication to Finding a Cure

To deliver on the promise of our novel immunotherapy platform, we have assembled a senior leadership team with multi-disciplinary expertise in drug development, cancer immunotherapy, combination drug/device cancer therapy & clinical trials.

CHARLES J. LINK, MD

Executive Chairman & Chief Medical Officer

EAMONN HOBBS

President & Chief Executive Officer

JOSEPH GERARDI

Chief Financial Officer

MARIO MAUTINO, PHD

Chief Scientific Officer

AGUSTIN GAGO

Chief Business Officer

MARLENE BARTON

EVP, Regulatory Affairs – Medical Device

GABRIELA ROSSI, PHD

EVP, Immunology & Grant Management

JASON RIFKIN

EVP, Clinical Affairs

STEPHEN KEE, MD

EVP, Clinical Operations

DAN RECINELLA

EVP, Medical Device Development

DANIELLE HOBBS

EVP, Investor Relations & Corporate Communications

Disclaimers: The content on this website is intended for US healthcare professionals only. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the US Food and Drug Administration.